Publications

Our research findings, patents and databases

代表性论文

HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2

Cao J, Sun L, Aramsangtienchai P, Spiegelman NA, Zhang X, Huang W, Seto E, Lin H*

The smallest histone deacetylase (HDAC) and the only class IV HDAC member, HDAC11, is reported to regulate immune activation and tumorigenesis, yet its biochemical function is largely unknown. Here we identify HDAC11 as an efficient lysine defatty-acylase that is >10,000-fold more efficient than its deacetylase activity...

Proc Natl Acad Sci U S A. 2019 Mar

DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase

Cao J#, Chen X#, Jiang L, Lu B, Yuan M, Zhu D, Zhu H, He Q, Yang B, Ying M*

Ferroptosis is a newly characterized form of regulated cell death mediated by iron-dependent accumulation of lipid reactive oxygen species and holds great potential for cancer therapy...

Nat Commun. 2020 Mar

Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells.

Cao J＃, Wang Y#, Dong R, Lin G, Zhang N, Wang J, Lin N, Gu Y, Ding L, Ying M, He Q, Yang B

Intratumoral hypoxia occurs in many solid tumors, where it is associated with the development of metastatic character. However, the connections between these phenomena are not fully understood. In this study, we define an integrative role for the E3 ubiquitin ligase subunit WSB1. In primary osteosarcomas, increased levels of WSB1 correlated with pulmonary metastatic potential.

Cancer Res. 2015 Nov

ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression

Yuan M#, Chen X#, Sun Y, Jiang L, Xia Z, Ye K, Jiang H, Yang B, Ying M, Cao J*, He Q*

The membrane protein claudin-3 (CLDN3) is critical for the formation and maintenance of tight junction and its high expression has been implicated in dictating malignant progression in various cancers. However, the post-translational modification of CLDN3 and its biological function remains poorly understood...

Acta Pharm Sin B. 2020 Aug

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

Li K#, You J#, Wu Q, Meng W, He Q, Yang Bo, Zhu C*, Cao J*

Synthetic lethality is a proven effective antitumor strategy that has attracted great attention. Large-scale screening has revealed many synthetic lethal genetic phenotypes, and relevant small-molecule drugs have also been implemented in clinical practice...

Acta Pharm Sin B. 2021 Sep

WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit.

Gao X, You J, Gong Y, Yuan M, Zhu H, Fang L, Zhu H, Ying M, He Q, Yang B, Cao J.

The dysregulation of transcription factors is widely associated with tumorigenesis. As the most well-defined transcription factor in multiple types of cancer, c-Myc can transform cells by transactivating various downstream genes...

Acta Pharm Sin B. 2022 Mar

TGSA: Protein-Protein Association-Based Twin Graph Neural Networks for Drug Response Prediction with Similarity Augmentation

Zhu Y#, Ouyang Z#, Chen W, Feng W, Chen Z, Cao J*, Wu J*.

Drug response prediction (DRP) plays an important role in precision medicine (e.g. for cancer analysis and treatment). Recent advances in deep learning algorithms make it possible to predict drug responses accurately based on genetic profiles...

Bioinformatics. 2021 Sep

PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.

Zhu HY, Du C, Yuan M, Fu P, He Q, Yang B, Cao J*

Despite extensive research into adjuvant and neoadjuvant chemotherapy, triple-negative breast cancer (TNBC) remains a common breast cancer (BC) subtype with poor prognosis. Given that it has higher immune cell infiltration, theoretically, it should be a protagonist of potential BC immunotherapies...

Drug Discov Today. 2020 Sep

Progress and perspective of organoid technology in cancer-related translational medicine.

Lin Y, Jiang L, He Q, Yuan M*, Cao J*

Organoids are in vitro simplified and miniature microcosms of internal organs, which have aroused great interest in tissue development, multiple disease models, clinical diagnosis, as well as high-throughput drug screening and personalized medicine and so on...

Biomed Pharmacother. 2022 Mar

Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis.

Che JX#, Jin ZG#, Yan FJ#, You JQ#, Xie JF, Chen BH, Cheng G, Zhu H, He QJ, Hu YZ, Yang B, Cao J*, Dong XW*

The gain of cell motility is an essential prerequisite for cancer metastasis. The ubiquitin ligase subunit WD repeat and SOCS box-containing 1 (WSB1) has been demonstrated to regulate hypoxia-driven tumor cell migration...

J Med Chem. 2021 Jun

研究成果

  1. Progress and perspective of organoid technology in cancer-related translational medicine.

    Biomed Pharmacother. 2022 Mar

  2. WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit.

    Acta Pharm Sin B. 2022 Mar

  3. Tumor immunity: a novel dimension for PROTACs to conquer cancer?

    Acta Pharmacol Sin. 2022 Jan

  4. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin

    Eur J Pharmacol. 2021 Oct

  5. Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy.

    Front Pharmacol. 2021 Sep

  6. TGSA: Protein-Protein Association-Based Twin Graph Neural Networks for Drug Response Prediction with Similarity Augmentation

    Bioinformatics. 2021 Sep

  7. Beyond iron deposition: making sense of the latest evidence on ferroptosis in Parkinson's disease

    Acta Pharmacol Sin. 2021 Sep

  8. Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

    Acta Pharm Sin B. 2021 Sep

  9. The C terminus of DJ-1 determines its homodimerization, MGO detoxification activity and suppression of ferroptosis.

    Acta Pharmacol Sin. 2021 Jul;

  10. Bis-isatin derivatives: design, synthesis, and biological activity evaluation as potent dimeric DJ-1 inhibitors

    Acta Pharmacol Sin. 2021 Jul

  11. Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis.

    J Med Chem. 2021 Jun

  12. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

    Acta Pharmacol Sin. 2021 Jan

  13. The role of autophagy in targeted therapy for acute myeloid leukemia.

    Autophagy. 2020 Sep

  14. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.

    Drug Discov Today. 2020 Sep

  15. Protein phase separation: A novel therapy for cancer?

    Br J Pharmacol. 2020 Aug

  16. ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression

    Acta Pharm Sin B. 2020 Aug

  17. N-myristoylation: from cell biology to translational medicine.

    Acta Pharmacol Sin. 2020 Aug

  18. DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase

    Nat Commun. 2020 Mar

  19. Stress granule: a promising target for cancer treatment.

    Br J Pharmacol. 2019 Dec

  20. Neohesperidin Prevents Colorectal Tumorigenesis by Altering the Gut Microbiota.

    Pharmacol Res. 2019 Oct;

  21. Identification of PRDX6 as a regulator of ferroptosis

    Acta Pharmacol Sin. 2019 Oct

  22. Activity-Guided Design of HDAC11-Specific Inhibitors.

    ACS Chem Biol. 2019 Jul

  23. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.

    J Med Chem. 2019 Apr

  24. HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2

    Proc Natl Acad Sci U S A. 2019 Mar

  25. A Small-Molecule SIRT2 Inhibitor That Promotes K-Ras4a Lysine Fatty-Acylation

    ChemMedChem. 2019 Feb

  26. 2-Bromopalmitate sensitizes osteosarcoma cells to adriamycin-induced apoptosis via the modulation of CHOP

    Eur J Pharmacol. 2019 Feb

  27. LncRNA-MM2P Identified as a Modulator of Macrophage M2 Polarization

    Cancer Immunol Res.2019 Feb

  28. Cellular Senescence and Anti-Cancer Therapy

    Curr Drug Targets. 2019 Jan

  29. Immune cells in the tumour: new routes of retinoids for chemoprevention and chemotherapeutics

    Br J Pharmacol. 2018 Dec

  30. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.

    ChemMedChem. 2018 Sep

  31. Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2.

    Blood. 2018 May

  32. CT-707 targets intratumor hypoxia of liver cancer by interrupting hypoxia-activated IGF-1R-YAP axis.

    Cancer Research. 2018 April

  33. Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b

    ACS Cent Sci. 2018 Jan

  34. The Role of Ferroptosis in Cancer Development and Treatment Response.

    Front Pharmacol. 2018 Jan

  35. AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.

    Theranostics. 2018 Jan

  36. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.

    Int J Cancer. 2017 Sep

  37. S-Palmitoylation of Junctional Adhesion Molecule C Regulates Its Tight Junction Localization and Cell Migration.

    J Biol Chem. 2017 Mar

  38. Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy

    Front Pharmacol. 2017 Mar

  39. The involvement of M2 macrophage polarization inhibition in fenretinide-mediated chemopreventive effects on colon cancer.

    Cancer Lett. 2017 Mar

  40. SIRT7 Is an RNA-Activated Protein Lysine Deacylase.

    ACS Chem Biol. 2017 Jan

  41. DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan

    Cancer Lett. 2016 Dec

  42. Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells.

    Cancer Res. 2015 Nov

  43. Ougan (Citrus reticulata cv. Suavissima) flavedo extract suppresses cancer motility by interfering with epithelial-to-mesenchymal transition in SKOV3 cells

    Chin Med. 2015 Jun

  44. Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

    RSC Adv., 2015 May

  45. DJ-1 as a human oncogene and potential therapeutic target.

    Biochem Pharmacol. 2015 Feb

  46. Tumor hypoxia enhances Non-Small Cell Lung Cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling.

    Oncotarget. 2014 Oct

  47. The oxidation states of DJ-1 dictate the cell fate in response to oxidative stress triggered by 4-HPR: autophagy or apoptosis.

    Antioxidants & Redox Signaling. 2014 Oct

  48. Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1α.

    Biochem Pharmacol. 2014 May

  49. Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway

    PLoS One. 2010 Nov

  50. YQ36: a novel bisindolylmaleimide analogue induces KB/VCR cell death.

    J Biomed Biotechnol. 2009 Jan

数据库

Qselected

Innovative algorithms developed by Queshi ensure that patients receive the most effective drug interventions in the shortest possible time.